Characterization of Anticoagulant Heparin and Related Polysaccharides
Characterization of Anticoagulant Heparin and Related Polysaccharides
批准号:
7939713
负责人:
ROBERT J LINHARDT
金额:
$55.2万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-08-31
关键词:
API 2AcademiaAddressAdverse eventAdverse reactionsAllergicAnticoagulantsApplications GrantsArtsBiologicalBiological AssayCardiologyCaringCessation of lifeCharacteristicsChemical StructureChondroitin SulfatesClinicClinicalComplexDelawareDermatan SulfateDevelopmentDigestionDisaccharidesDoseEnsureEventFamily suidaeFibrinolytic AgentsFoundationsFutureGlycosaminoglycansGrantHealthHealthcare SystemsHematologyHemodialysisHemorrhageHeparinHeterogeneityHigh Pressure Liquid ChromatographyHome environmentHospitalsIndividualIndustryInfant formulaInformaticsIngestionInorganic SulfatesIntestinal MucosaInvestigationKidney DiseasesMass Spectrum AnalysisMeasuresMedicalMedical centerMelamineMolecularMonitorNatureNuclear Magnetic ResonanceOperative Surgical ProceduresPatientsPharmaceutical PreparationsPharmacologic SubstancePlant RootsPolysaccharidesPositioning AttributePostoperative PeriodPreparationPreventionProductionProteinsPublic HealthQuality ControlReactionReportingSerious Adverse EventSolutionsSourceStructureTechniquesTechnologyTestingThinkingThrombosisTimeUnited StatesUnspecified or Sulfate Ion SulfatesVenous ThrombosisViralanalytical methodbasecostdesignexperienceglobal healthimprovedmeetingsmembermultidisciplinarypreventprophylacticpublic health relevancevigilance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Heparin is a suflated polysaccharide mixture that is widely used as baseline therapy in a number of clinical situations, especially for preventing thrombosis. While heparin has been administered in the clinic for the past several decades, recently, clusters of serious allergic-type events were reported in patients undergoing hemodialysis who were receiving heparin causing a global health crisis. Within a matter of weeks from the time of this crisis, a multidisciplinary team that comprised of members from academia (including co-PIs of this proposal), FDA and industry identified an unnatural contaminant, over sulfated chondroitin sulfate (OSCS), in the heparin lots associated with the adverse reactions. Despite the fact that, in the last 20 years, a number of scientific studies identified analytical techniques, which have defined molecular level characteristics of heparin, including composition and sequence, this critical pharmaceutical agent was primarily controlled and dosed on the basis of activity, prior to this heparin crisis. Unfortunately, the activity assays have not been able to distinguish the heterogeneity arising from other sulfated polysaccharides that have been able to "hide behind" heparin. The solution to this crisis, therefore emphasizes the importance of incorporating more detailed analytical characterization to monitor and control the heterogeneity in heparins to avoid such a serious health crisis in the future. In this proposal we seek to structurally and functionally define heparin using a set of well developed and robust analytical and structure-function assays. The information on heparin obtained from these assays would enable us to construct filters for monitoring and controlling the quality of heparin. Finally we seek to develop an informatics platform to capture and disseminate the structural parameters that capture the macro- and microheterogeneity of heparin to compare them against well defined standards. The informatics platform would be critical to rapidly disseminate the findings from this proposal to improve current quality control measures for heparin.
PUBLIC HEALTH RELEVANCE:
The recent global health crisis due to contaminated lots of heparin has elevated the importance of measuring and controlling the structural heterogenetiy of complex polysaccharide drugs like heparin. In this proposal we seek to build on our experience and expertise in employing robust analytical methods to structurally and functionally define heparin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heparan Sulfate 3-O-Sulfation in Transcellular Propagation of Tauopathy in Alzheimer's Disease
-
批准号:10054740
-
项目类别:
-
资助金额:$259.51万
-
财政年份:2020
-
负责人:ROBERT J LINHARDT
-
依托单位:
Endothelial glycocalyx reconstitution during sepsis
-
批准号:8803172
-
项目类别:
-
资助金额:$69.7万
-
财政年份:2014
-
负责人:ROBERT J LINHARDT
-
依托单位:
Endothelial glycocalyx reconstitution during sepsis
-
批准号:9278256
-
项目类别:
-
资助金额:$66.49万
-
财政年份:2014
-
负责人:ROBERT J LINHARDT
-
依托单位:
Endothelial glycocalyx reconstitution during sepsis
-
批准号:8927683
-
项目类别:
-
资助金额:$65.85万
-
财政年份:2014
-
负责人:ROBERT J LINHARDT
-
依托单位:
Endothelial glycocalyx reconstitution during sepsis
-
批准号:9066215
-
项目类别:
-
资助金额:$66.67万
-
财政年份:2014
-
负责人:ROBERT J LINHARDT
-
依托单位:
2012 Proteoglycans Gordon Research Conference
-
批准号:8314644
-
项目类别:
-
资助金额:$1.3万
-
财政年份:2012
-
负责人:ROBERT J LINHARDT
-
依托单位:
2010 Proteoglycans Gordon Conference
-
批准号:7902729
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2010
-
负责人:ROBERT J LINHARDT
-
依托单位:
Characterization of Anticoagulant Heparin and Related Polysaccharides
-
批准号:7853484
-
项目类别:
-
资助金额:$72.11万
-
财政年份:2009
-
负责人:ROBERT J LINHARDT
-
依托单位:
Heparin Glycan Microarray for Screening
-
批准号:7421026
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2007
-
负责人:ROBERT J LINHARDT
-
依托单位:
Stable Carbohydrate Libraries in Infectious Disease
-
批准号:7748958
-
项目类别:
-
资助金额:$38.08万
-
财政年份:2007
-
负责人:ROBERT J LINHARDT
-
依托单位:
Stable Carbohydrate Libraries in Infectious Disease
-
批准号:8006395
-
项目类别:
-
资助金额:$37.7万
-
财政年份:2007
-
负责人:ROBERT J LINHARDT
-
依托单位:
Heparin Glycan Microarray for Screening
-
批准号:7218331
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2007
-
负责人:ROBERT J LINHARDT
-
依托单位:
Stable Carbohydrate Libraries in Infectious Disease
-
批准号:7195311
-
项目类别:
-
资助金额:$40.71万
-
财政年份:2007
-
负责人:ROBERT J LINHARDT
-
依托单位:
Stable Carbohydrate Libraries in Infectious Disease
-
批准号:7336367
-
项目类别:
-
资助金额:$38.46万
-
财政年份:2007
-
负责人:ROBERT J LINHARDT
-
依托单位:
Stable Carbohydrate Libraries in Infectious Disease
-
批准号:7541797
-
项目类别:
-
资助金额:$38.46万
-
财政年份:2007
-
负责人:ROBERT J LINHARDT
-
依托单位:
SYNTHESIS OF GLYCOSAMINOGLYCAN OLIGOSACCHARIDES
-
批准号:6260455
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2000
-
负责人:ROBERT J LINHARDT
-
依托单位:
SYNTHESIS OF GLYCOSAMINOGLYCAN OLIGOSACCHARIDES
-
批准号:6684167
-
项目类别:
-
资助金额:$25.16万
-
财政年份:2000
-
负责人:ROBERT J LINHARDT
-
依托单位:
Chemoenzymatic Synthesis of Glycosaminoglycan Oligos
-
批准号:7183499
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2000
-
负责人:ROBERT J LINHARDT
-
依托单位:
SYNTHESIS OF GLYCOSAMINOGLYCAN OLIGOSACCHARIDES
-
批准号:6625285
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2000
-
负责人:ROBERT J LINHARDT
-
依托单位:
Chemoenzymatic Synthesis of Glycosaminoglycan Oligos
-
批准号:7580980
-
项目类别:
-
资助金额:$35.95万
-
财政年份:2000
-
负责人:ROBERT J LINHARDT
-
依托单位:
海外基金